• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Optinose









Many of us have expected the downfall of the nose for well over a year now and it hasn't happened. Something that popped up on my LinkedIn feed today seems to indicate that they are currently in the middle of a launch meeting. I would assume that is the CR indication. Wonder what that's going to do. That stock might be a good buy for a short-term gain.
 




Many of us have expected the downfall of the nose for well over a year now and it hasn't happened. Something that popped up on my LinkedIn feed today seems to indicate that they are currently in the middle of a launch meeting. I would assume that is the CR indication. Wonder what that's going to do. That stock might be a good buy for a short-term gain.
This guy nose what he’s talking about.